PRINCETON, N.J. and SAN DIEGO, Sept. 13 /PRNewswire/ -- Tobira Therapeutics
Inc., a clinical stage biotechnology company committed to research and product
discovery for the treatment of life-threatening and life-altering infectious
diseases, today announced results from an in vitro study evaluating TBR-652 in
combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir
(TDF), etravirine (ETV), and raltegravir (RAL) using the infectious
replicative assay deCIPhR. Cytotoxicity (cell number, morphology) was also
assessed. The average 50% inhibitory concentration (IC50) for TBR-652 was
0.99+0.19 (range 0.72-1.43) nM. Weak synergy was seen in combinations of
TBR-652 with LPV (IC50 26.90-40.27 nM), ATV (IC50 57.66-78.89 nM), DRV (IC50
2.12-2.78 nM) and ETV (IC50 71.77-83.35 nM). Additive effects were seen with
TBR-652 plus TDF (IC50 10.66-11.13 nM) or RAL (IC50 29.66-103.72nM).
Importantly, no antagonism and no cytoxicity were observed with any 2-drug
combination at any concentration tested.
